1 Disability (primary analysis) |
2 |
2829 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.01 [‐0.09, 0.06] |
1.1 Fluoxetine |
2 |
2829 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.01 [‐0.09, 0.06] |
2 Independent on modified Rankin score (mRS 0 to 2) (primary analysis) |
3 |
3249 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.91, 1.09] |
3 Neurological deficit score |
2 |
142 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.30 [‐0.63, 0.04] |
3.1 Fluoxetine |
2 |
142 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.30 [‐0.63, 0.04] |
4 Depression (continuous data) |
2 |
2861 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.11 [‐0.19, ‐0.04] |
4.1 Fluoxetine |
2 |
2861 |
Std. Mean Difference (IV, Fixed, 95% CI) |
‐0.11 [‐0.19, ‐0.04] |
5 Depression (dichotomous data) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
5.1 Fluoxetine |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
6 Death |
3 |
3254 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.79, 1.25] |
6.1 Fluoxetine |
3 |
3254 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.79, 1.25] |
7 Seizures |
3 |
3275 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.47 [0.99, 2.18] |
7.1 Fluoxetine |
3 |
3275 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.47 [0.99, 2.18] |
8 Gastrointestinal side effects |
2 |
148 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.19 [1.00, 4.76] |
8.1 Fluoxetine |
2 |
148 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.19 [1.00, 4.76] |
9 Bleeding |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
9.1 Fluoxetine |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
10 Leaving the trial before the end of scheduled follow‐up |
3 |
3277 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.48, 2.10] |
10.1 Fluoxetine |
3 |
3277 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.48, 2.10] |
11 Motor deficits |
3 |
2936 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.02 [‐0.05, 0.09] |
11.1 Fluoxetine |
3 |
2936 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.02 [‐0.05, 0.09] |
12 Disability (sensitivity analyses all studies regardless of RoB) |
26 |
5334 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.23 [0.18, 0.29] |
12.1 Fluoxetine |
15 |
3919 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.14 [0.08, 0.20] |
12.2 Sertraline |
1 |
130 |
Std. Mean Difference (IV, Fixed, 95% CI) |
1.38 [0.99, 1.76] |
12.3 Paroxetine |
5 |
293 |
Std. Mean Difference (IV, Fixed, 95% CI) |
1.29 [1.03, 1.55] |
12.4 Citalopram |
5 |
992 |
Std. Mean Difference (IV, Fixed, 95% CI) |
0.24 [0.11, 0.37] |
13 Independent on modified Rankin score (mRS 0 to 2) (sensitivity analysis) |
5 |
4002 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.91, 1.03] |
13.1 Fluoxetine |
3 |
3249 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.91, 1.09] |
13.2 Sertraline |
1 |
111 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.0 [0.97, 1.04] |
13.3 Citalopram |
1 |
642 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.82, 0.98] |